An umbrella review examined multiple studies on curcumin formulations for treating osteoarthritis. The analysis looked at how these supplements compared to non-steroidal anti-inflammatory drugs, commonly known as NSAIDs. The review included studies with varying designs and curcumin compositions. Researchers found that curcumin led to significant improvements in pain and joint function or stiffness. These benefits were comparable to the effects seen with NSAIDs. The review also noted that curcumin had a more favorable tolerability profile in the available studies. Safety data were incomplete across the reviews, and serious adverse events were not reported in detail. The studies showed substantial differences in how curcumin was made and taken. Only three studies were rated as high quality by the review standards. Because of these variations and limited data, definitive conclusions about which formulation is best are not possible. Readers should understand that while curcumin shows promise for symptom management, more research is needed to confirm these findings and establish optimal dosing.
Umbrella review suggests curcumin may offer comparable efficacy and better tolerability than NSAIDs for osteoarthritisCurcumin shows promise for osteoarthritis pain with fewer side effects than NSAIDs
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note curcumin shows comparable efficacy and better tolerability than NSAIDs for osteoarthritis, but data are limited.
This umbrella review evaluates curcumin formulations compared to non-steroidal anti-inflammatory drugs (NSAIDs) for managing osteoarthritis symptoms. The scope includes pain, joint function, tolerability, and safety outcomes across available studies. The authors explicitly state that the population, sample size, and setting were not reported in the source data.
Key synthesized findings indicate significant improvements in pain measured by VAS and joint function or stiffness measured by WOMAC with curcumin. Efficacy signals for curcumin are described as comparable to NSAIDs. Additionally, the review notes a more favorable tolerability profile for curcumin compared to NSAIDs in the available studies. Specific effect sizes, absolute numbers, and p-values were not reported for these outcomes.
The authors highlight substantial limitations, including limited data overall and substantial heterogeneity in formulations and study designs. Only three studies were rated as high quality by AMSTAR-2. Variations in curcumin composition, bioavailability-enhancing strategies, and extraction methods further complicate interpretation. The absence of direct comparative analyses among formulations and incomplete safety reporting across reviews are also noted as constraints.
Practice relevance is tempered by these uncertainties. While curcumin-based interventions show promise for osteoarthritis symptom management, definitive conclusions regarding superiority over NSAIDs or optimal formulations are not supported by the current evidence base.
What this means for you:
Curcumin may help osteoarthritis pain and function as well as NSAIDs with fewer side effects in available studies. More on Osteoarthritis
Chronic ACL deficiency increases risk of moderate to severe arthritis compared to reconstruction
ACL injuries and surgery impact long term risk of arthritis
This meta-analysis of matched cohort studies evaluates the risk of osteoarthritis in patients with chronic anterior cruciate ligament (ACL) …
People with torn ACL ligaments face higher risks of severe joint arthritis over time, especially if they undergo certain surgical procedures…
Peripheral mechanisms like proton-sensing channels and neurovascular remodeling contribute to pain in osteoarthritis
New research explores why osteoarthritis pain becomes hard to treat
This narrative review explores the complex pathophysiology of osteoarthritis pain, highlighting roles such as proton-sensing nociceptor acti…
Pain from osteoarthritis may be driven by nerve changes and inflammation, making it harder for doctors to manage as the condition progresses…
Curcumin reduces tumor weight and volume in preclinical models of breast cancer
Curcumin Shows Potential to Reduce Breast Cancer Tumors in Lab Models
This meta-analysis of preclinical animal models indicates that curcumin significantly reduces tumor weight (SMD -1.65) and volume (SMD -2.47…
Early laboratory studies show that curcumin may reduce tumor size and slow cell growth in breast cancer models, though more human research i…
Circadian misalignment associated with increased risk of osteoporosis, sarcopenia, and osteoarthritis
Circadian Disruption Linked to Bone and Muscle Loss
This narrative review examines the impact of circadian disruption on musculoskeletal health, specifically regarding bone loss, muscle protei…
Shift work and irregular eating may harm bones and muscles. A new review explains how.
View Original Abstract ↓
BackgroundThis umbrella review synthesizes evidence from systematic reviews and meta-analyses evaluating the efficacy and safety of diverse curcumin formulations in the treatment of osteoarthritis (OA). The objective is to assess curcumin’s therapeutic potential and inform future formulation development.MethodsA systematic search was conducted across PubMed, Web of Science, Cochrane, Embase, Scopus, and MEDLINE up to September 2025 to identify systematic reviews and meta-analyses investigating curcumin for OA (requiring at least one randomized controlled trial). Methodological quality was assessed using AMSTAR-2. Due to limited data and substantial heterogeneity in formulations and study designs, findings were synthesized qualitatively.ResultsTen meta-analyses and systematic reviews were included. Curcumin formulations exhibited significant improvements in pain (VAS) and joint function/stiffness (WOMAC), showing efficacy signals comparable to non-steroidal anti-inflammatory drugs (NSAIDs) and a more favorable tolerability profile in the available studies. However, methodological and clinical heterogeneity was substantial (AMSTAR-2 rated only three studies as high quality). Variations in curcumin composition, bioavailability-enhancing strategies, and extraction methods, coupled with the absence of direct comparative analyses among formulations, precluded definitive inter-group comparisons.ConclusionCurcumin-based interventions show promise for OA symptom management, with efficacy signals comparable to NSAIDs and appear to have a more favorable tolerability profile in the available studies, while addressing bioavailability challenges. Nevertheless, pronounced heterogeneity and the lack of head-to-head comparative studies, and incomplete safety reporting across reviews preclude definitive conclusions regarding superiority over NSAIDs or optimal formulations, and formulation-specific inferences remain limited. Future research should prioritize high-quality comparative trials or network meta-analyses to confirm efficacy signals and enable formulation-specific inferences.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier CRD420251172722.
Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management
Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms
Related in Rheumatology
Evaluating Treat to Target Outcomes in Elderly and Young Rheumatoid Arthritis Patients
Treat-to-Target Strategy Shows Promise for Elderly Rheumatoid Arthritis
A multicenter trial confirms that elderly patients achieve similar clinical outcomes and safety profiles as younger cohorts under a standard…
A new study shows that elderly patients with rheumatoid arthritis can achieve similar results to younger patients using a standard treat-to-…
Belimumab linked to higher remission and low disease activity rates in SLE without glucocorticoids
Trial shows belimumab improves remission rates for lupus patients
A post hoc analysis of phase III trials found that belimumab plus standard therapy led to higher rates of DORIS remission and LLDAS attainme…
A new analysis of clinical trials shows that the drug belimumab helps more people with lupus reach specific remission goals compared to a pl…
Upadacitinib 15 mg daily achieves DAS28-CRP ≤3.2 in 43.3% of patients versus 22.4% for adalimumab
Trial shows upadacitinib outperforms adalimumab for rheumatoid arthritis patients
This randomized controlled trial of 492 patients with rheumatoid arthritis and prior TNFi failure found upadacitinib 15 mg daily superior to…
A new trial finds that upadacitinib works better than adalimumab for people with rheumatoid arthritis who did not respond well to previous t…
Deucravacitinib modulates up to 2529 genes and SLE-relevant gene sets including interferon-regulated genes
Trial Shows Deucravacitinib Modulates Gene Activity in Lupus Patients
This post hoc analysis of a Phase 2 trial in 363 patients with systemic lupus erythematosus (SLE) found that deucravacitinib modulated up to…
A Phase 2 trial shows that deucravacitinib may influence specific gene sets and immune cell activity in people with systemic lupus erythemat…
From Other Specialties
Preoperative tranexamic acid did not reduce transfusion rates in geriatric patients with hip fractures
Trial shows tranexamic acid does not reduce hip fracture transfusions
This randomized controlled trial of 283 geriatric patients with hip fractures found no significant difference in postoperative transfusion b…
A new trial of 283 patients found that the drug tranexamic acid did not reduce the need for blood transfusions after hip fracture surgery.
Cefdinir and cefprozil show superior eradication rates compared to penicillin V for Group A streptococcal pharyngitis
Certain antibiotics work better than others for strep throat
This network meta-analysis of 64 RCTs involving 23,287 participants evaluated 24 antibiotics for Group A streptococcal (GAS) pharyngitis. Th…
New data shows that while some antibiotics effectively clear strep throat, azithromycin performs poorly and carries more risks.
Adalimumab and its biosimilar IBI303 show distinct response clusters in ankylosing spondylitis
Trial shows two different ways patients respond to adalimumab
This Phase III randomized controlled trial of 438 patients with active ankylosing spondylitis identified two longitudinal response clusters.…
A new study identifies two distinct groups of people with ankylosing spondylitis who react differently to the same treatment.
Intramedullary nailing shows lower odds of nonunion and infection than sliding hip screws
Intramedullary nailing shows better outcomes for unstable hip fractures
This meta-analysis of randomized controlled trials involving 3237 patients with unstable trochanteric femoral fractures found that intramedu…
Patients with unstable hip fractures may experience less pain and fewer complications when treated with intramedullary nailing instead of sl…